(0.18%) 5 109.08 points
(0.26%) 38 340 points
(0.04%) 15 934 points
(-0.32%) $83.58
(2.60%) $1.973
(-0.28%) $2 340.70
(-0.23%) $27.47
(2.70%) $947.00
(0.02%) $0.935
(-0.03%) $11.02
(-0.21%) $0.799
(1.62%) $93.36
Live Chart Being Loaded With Signals
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People's Republic of China...
Stats | |
---|---|
本日の出来高 | 7.09M |
平均出来高 | 7.51M |
時価総額 | 17.70B |
EPS | HKD0 ( 2024-03-26 ) |
Last Dividend | HKD0.342 ( 2023-09-11 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 6.81 |
ATR14 | HKD0.00800 (0.11%) |
ボリューム 相関
China Medical System 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
China Medical System 相関 - 通貨/商品
China Medical System 財務諸表
Annual | 2023 |
収益: | HKD8.01B |
総利益: | HKD6.11B (76.24 %) |
EPS: | HKD0.980 |
FY | 2023 |
収益: | HKD8.01B |
総利益: | HKD6.11B (76.24 %) |
EPS: | HKD0.980 |
FY | 2022 |
収益: | HKD9.15B |
総利益: | HKD7.04B (76.89 %) |
EPS: | HKD1.330 |
FY | 2021 |
収益: | HKD8.34B |
総利益: | HKD6.25B (74.93 %) |
EPS: | HKD1.221 |
Financial Reports:
No articles found.
China Medical System Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0.337 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.274 (N/A) |
HKD0.342 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.00693 | 2011-03-22 |
Last Dividend | HKD0.342 | 2023-09-11 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 26 | -- |
Total Paid Out | HKD3.99 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.6 | -- |
Div. Sustainability Score | 9.69 | |
Div.Growth Potential Score | 5.90 | |
Div. Directional Score | 7.80 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
9909.HK | Ex Dividend Knight | 2023-11-24 | Semi-Annually | 0 | 0.00% | |
2161.HK | Ex Dividend Junior | 2023-08-15 | Annually | 0 | 0.00% | |
1161.HK | Ex Dividend Knight | 2023-06-12 | Annually | 0 | 0.00% | |
0239.HK | Ex Dividend Knight | 2023-09-29 | Semi-Annually | 0 | 0.00% | |
3866.HK | Ex Dividend Junior | 2023-06-02 | Annually | 0 | 0.00% | |
1731.HK | Ex Dividend Junior | 2023-06-23 | Sporadic | 0 | 0.00% | |
0771.HK | Ex Dividend Junior | 2023-05-31 | Sporadic | 0 | 0.00% | |
2327.HK | Ex Dividend Junior | 2023-08-03 | Sporadic | 0 | 0.00% | |
1290.HK | Ex Dividend Junior | 2023-06-14 | Sporadic | 0 | 0.00% | |
0363.HK | Ex Dividend Knight | 2023-06-01 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.300 | 1.500 | 4.01 | 6.01 | [0 - 0.5] |
returnOnAssetsTTM | 0.135 | 1.200 | 5.49 | 6.58 | [0 - 0.3] |
returnOnEquityTTM | 0.152 | 1.500 | 9.42 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.567 | -1.000 | 4.33 | -4.33 | [0 - 1] |
currentRatioTTM | 4.29 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 3.85 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.10 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0734 | -1.500 | 8.78 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 1.021 | 2.00 | 9.66 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 1.010 | 2.00 | 9.50 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0839 | -1.500 | 9.66 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.758 | 1.000 | 0.696 | 0.696 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.339 | 1.000 | 5.23 | 5.23 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 1.923 | 1.000 | 0.429 | 0.429 | [0.2 - 2] |
assetTurnoverTTM | 0.452 | 0.800 | -0.320 | -0.256 | [0.5 - 2] |
Total Score | 9.69 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 6.91 | 1.000 | 9.40 | 0 | [1 - 100] |
returnOnEquityTTM | 0.152 | 2.50 | 9.63 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 1.010 | 2.00 | 9.66 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 9.11 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 1.021 | 2.00 | 9.66 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.567 | 1.500 | 4.33 | -4.33 | [0 - 1] |
pegRatioTTM | 0.342 | 1.500 | -1.052 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.312 | 1.000 | 4.69 | 0 | [0.1 - 0.5] |
Total Score | 5.90 |
China Medical System
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People's Republic of China. The company's products include Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu for the treatment of acute heart failure; Deanxit for the treating mild-to-moderate depression, anxiety, and psychosomatic affections; Ursofalk for the treatment of cholesterol gallstones in the gallbladder, cholestatic liver disease, and biliary reflux gastritis; Salofalk for treating Ulcerative Colitis and Crohn's disease; Bioflor for the treatment of diarrhea; Combizym for dyspepsia; Augentropfen Stulln Mono eye drops to treat senile macula degeneration and asthenopia; and Hirudoid for blunt traumata with or without hematomas and superficial phlebitis insofar. Its products also comprise DanShenTong capsules for treating acne, tonsillitis, otitis externa, boils, carbuncle, traumatic infection, burn infection, mastitis, cellulitis, osteomyelitis, etc.; XiDaKang, a protein hydrolysate oral solution; YiNuoShu for treating respiratory diseases; Ganfule capsules for the treatment of primary cancer of the liver; Imdur for the treatment of coronary heart disease, chronic heart failure, and myocardial infarction, as well as for prevention of vasospasm and mixed angina; and Parlodel tablets for the endocrine and neuro system indications. In addition, the company also offers Elcatonin injection for osteoporosis; YinlianQinggan granules for treating acute hepatitis A and chronic hepatitis B; Lamisil tablets for treating fungal infections on skin and hair; and MOVICOL for treating chronic constipation and faecal impaction. In addition, it is involved in the agriculture and livestock activities. The company was founded in 1995 and is headquartered in North Point, Hong Kong. China Medical System Holdings Limited is a subsidiary of Treasure Sea Limited.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。